| Name |
Axitinib, Free Base
|
| Supplier |
Biorbyt
|
| Catalog |
orb60991
|
| Prices |
$298.00, $400.00, $417.00, $748.00, $1,139.00, $1,913.00, $4,191.00
|
| Sizes |
50 mg, 100 mg, 200 mg, 500 mg, 1 g, 2 g, 5 g
|
| Cas Number |
[319460-85-0]
|
| Pubchem |
6450551
|
| Chemical Name |
N-methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamide
|
| Formula |
C22H18N4OS
|
| Molecular Weight |
386.47 g/mol
|
| Purity |
>99% pure
|
| Description |
Axitinib (AG-013736) is a multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ and c-Kit with IC50 of 0.1 nM, 0.2 nM, 0.1-0.3 nM, 1.6 nM and 1.7 nM, respectively. Axitinib is currently in Phase III clinical trial in advanced hepatocellular carcinoma. Axitinib is superior as second-line therapy compared with sorafenib, the current standard of care.
|
| Supplier Page |
Shop
|
